BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28423495)

  • 1. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.
    Macha MA; Rachagani S; Qazi AK; Jahan R; Gupta S; Patel A; Seshacharyulu P; Lin C; Li S; Wang S; Verma V; Kishida S; Kishida M; Nakamura N; Kibe T; Lydiatt WM; Smith RB; Ganti AK; Jones DT; Batra SK; Jain M
    Oncotarget; 2017 Mar; 8(13):20961-20973. PubMed ID: 28423495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells.
    Chen YW; Chen KH; Huang PI; Chen YC; Chiou GY; Lo WL; Tseng LM; Hsu HS; Chang KW; Chiou SH
    Mol Cancer Ther; 2010 Nov; 9(11):2879-92. PubMed ID: 21062915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
    Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
    Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
    Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
    Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.
    Torres MA; Raju U; Molkentine D; Riesterer O; Milas L; Ang KK
    Invest New Drugs; 2011 Aug; 29(4):554-61. PubMed ID: 20119866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Shintani S; Kiyota A; Mihara M; Sumida T; Kayahara H; Nakashiro K; Hamakawa H
    Am J Clin Oncol; 2003 Oct; 26(5):e150-6. PubMed ID: 14528090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
    Huang SM; Harari PM
    Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair.
    Kang KB; Zhu C; Wong YL; Gao Q; Ty A; Wong MC
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e43-52. PubMed ID: 22516386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
    Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
    Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells.
    Lo WL; Yu CC; Chiou GY; Chen YW; Huang PI; Chien CS; Tseng LM; Chu PY; Lu KH; Chang KW; Kao SY; Chiou SH
    J Pathol; 2011 Mar; 223(4):482-95. PubMed ID: 21294122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
    Huang SM; Li J; Armstrong EA; Harari PM
    Cancer Res; 2002 Aug; 62(15):4300-6. PubMed ID: 12154033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma.
    Yin X; Hayes DN; Shores CG
    Head Neck; 2011 Aug; 33(8):1106-14. PubMed ID: 20967867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of tumour initiating cells in feline head and neck squamous cell carcinoma and evidence for gefitinib induced epithelial to mesenchymal transition.
    Pang LY; Bergkvist GT; Cervantes-Arias A; Yool DA; Muirhead R; Argyle DJ
    Vet J; 2012 Jul; 193(1):46-52. PubMed ID: 22342216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
    De Schutter H; Kimpe M; Isebaert S; Nuyts S
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):904-12. PubMed ID: 19215824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear localization signal-enhanced RNA interference of EZH2 and Oct4 in the eradication of head and neck squamous cell carcinoma-derived cancer stem cells.
    Lo WL; Chien Y; Chiou GY; Tseng LM; Hsu HS; Chang YL; Lu KH; Chien CS; Wang ML; Chen YW; Huang PI; Hu FW; Yu CC; Chu PY; Chiou SH
    Biomaterials; 2012 May; 33(14):3693-709. PubMed ID: 22361100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.
    Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The enhancement of tumor radioresponse by combined treatment with cepharanthine is accompanied by the inhibition of DNA damage repair and the induction of apoptosis in oral squamous cell carcinoma.
    Harada T; Harada K; Ueyama Y
    Int J Oncol; 2012 Aug; 41(2):565-72. PubMed ID: 22664937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation.
    McNally LR; Rosenthal EL; Zhang W; Buchsbaum DJ
    Cancer Gene Ther; 2009 Mar; 16(3):246-55. PubMed ID: 18846112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.